Bronchogen
Also known as: Ala-Glu-Asp, AED, Lung Bioregulator, Respiratory Peptide Bioregulator
Bronchogen (AED) is a synthetic tripeptide (Ala-Glu-Asp) from the Khavinson bioregulator program targeting bronchial and lung tissue. It is researched for restoring respiratory epithelium function, reducing chronic airway inflammation, and supporting lung tissue repair in aging and chronic respiratory conditions.
Bronchogen is a 335.27 Da research peptide. Bronchogen (AED) is a synthetic tripeptide (Ala-Glu-Asp) from the Khavinson bioregulator program targeting bronchial and lung tissue. It is researched for restoring respiratory epithelium function, reducing chronic airway inflammation, and supporting lung tissue repair in aging and chronic respiratory conditions.
Also called: Ala-Glu-Asp, AED, Lung Bioregulator
335.27
Molecular Weight
Daltons
0
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
5000-10000
Typical Dose
mcg
Overview
Bronchogen is a synthetic tripeptide consisting of Alanine-Glutamic acid-Aspartic acid (AED), developed as a lung-specific bioregulator by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It was designed to target bronchial epithelial cells and lung parenchyma, modulating gene expression related to respiratory function, mucosal immunity, and tissue repair. In the Khavinson bioregulation framework, Bronchogen restores age-related and disease-related decline in respiratory tissue gene expression, supporting bronchial epithelial integrity, mucociliary clearance, and local immune defense. It has been studied in models of chronic obstructive pulmonary disease (COPD), bronchitis, and age-related respiratory decline. Available in Russia as an oral supplement, Bronchogen is typically used in 10-30 day courses and is often combined with other tissue-specific bioregulators. Research data is primarily from Russian institutions.
Key Takeaways: Bronchogen
- Research doses typically range from 5000 to 10000 mcg via oral capsule
- 0 benefits with strong evidence, 0 moderate, 4 preliminary
- Half-life: Minutes (typical of short peptides)
- 4 cited research studies in this guide
Mechanism of Action
Bronchogen is proposed to interact with DNA sequences in bronchial epithelial cells, modulating gene expression related to mucin production, surfactant synthesis, ciliary function, and local immune defense (secretory IgA, antimicrobial peptides). The tripeptide's small size allows cell membrane penetration without receptor-mediated mechanisms. Research suggests Bronchogen normalizes the expression of genes involved in bronchial epithelial differentiation, reduces chronic inflammatory gene expression (TNF-α, IL-6 in airway tissue), and supports mucosal barrier function. In COPD models, it has been reported to reduce airway remodeling and restore ciliary beat frequency. The peptide may also modulate local oxidant-antioxidant balance in lung tissue, reducing oxidative damage from chronic inflammation or environmental exposures.
Research Benefits
Bronchogen at a Glance
Bronchogen is proposed to interact with DNA sequences in bronchial epithelial cells, modulating gene expression related to mucin production, surfactant synthesis, ciliary function, and local immune defense (secretory IgA, antimicrobial peptides).
Bronchial Epithelial Restoration
PreliminaryResearch shows restoration of bronchial epithelial integrity and differentiation markers in aged and damaged respiratory tissue.
Respiratory Inflammation Reduction
PreliminaryCell and animal studies suggest reduced chronic airway inflammation with normalization of pro-inflammatory cytokine expression in bronchial tissue.
Mucociliary Function Support
PreliminaryProposed improvement in ciliary beat frequency and mucin regulation, supporting the lung's natural clearance mechanisms.
COPD and Chronic Bronchitis Support
PreliminaryStudied in models of chronic obstructive pulmonary disease as a complementary approach to restoring lung tissue function alongside standard treatment.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Oral capsule (Russian formulation) | 5000–10000 mcg | Oral capsule |
| Subcutaneous research protocol | 5000–10000 mcg | Subcutaneous injection |
Frequency
Once or twice daily during treatment courses
Timing
No specific timing requirements
Cycle Length
10-30 day courses, repeated 2-3 times per year
Research Notes
- 1Available in Russia as oral supplement capsules.
- 2Frequently combined with other Khavinson bioregulators.
- 3Most research from Russian institutions.
- 4No serious adverse effects reported.
Reconstitution Guide
Standard Reconstitution
Vial Size
10 mg
Bacteriostatic Water
2 mL
Concentration
50 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Bronchogen vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 2 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at Refrigerated (2-8°C) after reconstitution. Up to 30 days refrigerated.
Storage Temperature
Refrigerated (2-8°C) after reconstitution
Shelf Life
Up to 30 days refrigerated
Important Notes
- •Reconstitute with bacteriostatic water.
- •Small, stable tripeptide.
- •Most commonly used in oral capsule form.
Bronchogen Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Bronchogen Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Injection site reactions (mild)
- !No significant adverse effects reported
- !Well tolerated across published research
- !Mild GI discomfort with oral capsules (rare)
Potential Interactions
- ⚡Compatible with other Khavinson bioregulators.
- ⚡No adverse interactions with standard respiratory medications reported.
- ⚡Theoretical additive effects with anti-inflammatory respiratory agents.
- ⚡No interactions with inhaled corticosteroids reported.
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
AED peptide regulates gene expression in bronchial epithelium
Demonstrated Bronchogen modulates gene expression in bronchial epithelial cell cultures, affecting genes involved in cell differentiation, mucin production, and inflammatory signaling.
Bioregulatory peptides in chronic obstructive pulmonary disease
Reviewed the use of respiratory-specific peptide bioregulators including Bronchogen in models of COPD, showing improved respiratory function parameters and reduced airway inflammation.
Short peptides interact with DNA in tissue-specific manner
Molecular studies showing AED tripeptide interacts with specific DNA sequences in lung tissue cells, supporting the bioregulation mechanism of tissue-specific gene modulation.
Peptide bioregulators for respiratory system aging
Clinical observations in elderly patients with chronic respiratory conditions showing improved pulmonary function tests and symptom scores after Bronchogen treatment courses.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Bronchogen (AED) is a lung-specific tripeptide bioregulator from the Khavinson program. It targets bronchial and lung tissue to restore respiratory function, reduce airway inflammation, and support mucosal immunity.
In Russia, Bronchogen is available as oral capsules. It can also be administered by subcutaneous injection. Treatment courses are typically 10-30 days, repeated 2-3 times per year.
No. Bronchogen is researched as a complementary approach, not a replacement for standard respiratory treatment. Patients with COPD or other respiratory conditions should maintain their prescribed medications.
Research is primarily from Russian institutions with limited independent replication. Evidence is at the preliminary level, with mostly cell culture and small animal/observational studies.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.